The mystery surrounding Daiichi Sankyo Co. Ltd.'s filing plans for quizartinib in Europe has been solved with the news that the EMA has granted accelerated assessment to the company's closely watched acute myeloid leukemia (AML) candidate.
Daiichi Sankyo Seals Speedier Europe Review For Quizartinib
The acute myeloid leukemia drug is the lead candidate in the strong oncology pipeline the Japan-headquartered company has assembled over the past couple of years.
More from Anticancer
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.